REG - Renalytix PLC - Notice of Interim Results & Investor Presentation

RenalytixAnnouncement

12/03/2025 12:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250312:nRSL4024Aa&default-theme=true

RNS Number : 4024A  Renalytix PLC  12 March 2025

Renalytix plc

("Renalytix" or the "Company")

 

Notice of Interim Results and Investor Presentation

 

LONDON and NEW YORK, 12 March 2025 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY),
which is commercialising kidneyintelX.dkd, the only FDA-approved and Medicare
reimbursed prognostic test to support early-stage risk assessment for chronic
kidney disease, will announce its unaudited interim results for the six months
ended 31 December 2024 on Tuesday 18 March 2025.

 

Investor Presentations

 

On-line investor presentation

Julian Baines, Executive Chairman, will be hosting a live interactive
presentation on the Engage Investor platform, at 2:00pm (GMT) on 18 March
2025.

 

Renalytix welcomes all current shareholders and interested investors to join
and encourages investors to pre-submit questions. Investors can also submit
questions at any time during the live presentation.

 

Investors can sign up to Engage Investor at no cost and follow Renalytix plc
from their personalised investor hub. Register interest in this event here:
https://engageinvestor.news/RENX_IP25 (https://engageinvestor.news/RENX_IP25)

 

A recording of the event will be available on the Engage Investor platform
afterwards.

 

In-person investor presentation

Julian Baines will also provide an in-person presentation relating to the
Company's interim results at 5.30pm GMT on Tuesday 25 March 2025, which is
open to all existing and potential shareholders. The Company welcomes
investors to 75 King William Street, London, EC4N 7BE from 5.15pm for a 5.30pm
start and will be followed by refreshments.

 

If you would like to attend, please contact Walbrook PR on 020 7933 8780 or
email renalytix@walbrookpr.com.

 

 

For further information, please contact:

 

 Renalytix plc                                             www.renalytix.com (http://www.renalytix.com)
 James McCullough, CEO                                     Via Walbrook PR

 Stifel (Nominated Adviser and Joint Broker)               Tel: 020 7710 7600
 Nicholas Moore / Nick Harland / Brough Ransom / Ben Good

 Oberon Capital (Joint Broker)                             Tel: 020 3179 5300
 Mike Seabrook / Nick Lovering

 Walbrook PR Limited                                       Tel: 020 7933 8780 or renalytix@walbrookpr.com
 Paul McManus / Alice Woodings                             Mob: 07980 541 893 / 07407 804 654

 

About Renalytix (www.renalytix.com (http://www.renalytix.com) )

Renalytix (LSE: RENX) (OTCQB: RNLXY) is an artificial intelligence-enabled in
vitro diagnostics company, focused on optimizing clinical management of kidney
disease to drive improved patient outcomes. Renalytix has received FDA
approval and Medicare reimbursement for kidneyintelX.dkd which is now offered
commercially in the United States.

 

Unrecognized and uncontrolled kidney disease remains one of the largest
barriers to controlling cost and suffering in the United States and the United
Kingdom's medical system, affecting over 14 million and 8 million people,
respectively. After five years of development and clinical validation,
kidneyintelX.dkd is the only FDA-approved and Medicare reimbursed prognostic
tool capable of understanding a patient's risk with kidney disease early where
treatment has maximal effect. kidneyintelX.dkd is now being deployed across
large physician group practices and health systems in select regions of the
United States.

 

The over 10,000 patients that have been tested by kidneyintelX.dkd have
produced a substantial body of real-world performance data. In patient
populations where kidneyintelX.dkd has been deployed, a demonstrated and
significant increase in diagnosis, prognosis, and treatment rates have been
recorded. kidneyintelX.dkd now has full reimbursement established by Medicare,
the largest insurance payer in the United States, at $950 per reportable
result. kidneyintelX.dkd is also recommended for use in the international
chronic kidney disease clinical guidelines (KDIGO).

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORPKBBQDBKDAND